Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 8/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487107 | 0.92 | PIK3CA (0.40) | PDK2HSD17B1HSD17B2PIK3CAIMPDH2 | |
| SCHEMBL13488126 | 0.92 | PDK2 (0.46) | PDK2HSD17B1HSD17B2PIK3CAIMPDH2 | |
| SCHEMBL15977559 | 0.89 | PDK2 (0.49) | PDK2PIK3CAIMPDH2CDC7ROCK2 | |
| SCHEMBL13487277 | 0.89 | HSD17B1 (0.37) | PDK2HSD17B1HSD17B2MAPK14MAPK11 | |
| SCHEMBL13487896 | 0.88 | PDK2 (0.46) | PDK2HSD17B1HSD17B2PIK3CAIMPDH2 | |
| SCHEMBL13487720 | 0.88 | PDK2 (0.43) | PDK2HSD17B1HSD17B2PIK3CAIMPDH2 | |
| SCHEMBL13487360 | 0.88 | PDK2 (0.35) | PDK2 | |
| SCHEMBL13487357 | 0.88 | PDK2 (0.45) | PDK2HSD17B1HSD17B2PIK3CAMAP4K4 | |
| SCHEMBL13487361 | 0.88 | PDK2 (0.39) | PDK2 | |
| SCHEMBL13487174 | 0.88 | MAPK11 (0.38) | PDK2HSD17B1HSD17B2MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| EP-2108689-A2 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | PDK2 1456/4885HSD17B1 789/4885HSD17B2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.